Lilly's EloraTZP Brought Up to 77% of Adults With Diabetes to Normal Blood Sugar in Phase 2 Trial

Eli Lilly's experimental drug EloraTZP showed promising results in a Phase 2 trial, with up to 77% of adults with type 2 diabetes and obesity achieving normal blood sugar levels and 60% no longer meeting obesity criteria after 48 weeks. Participants in the best-performing group lost an average of 54.1 pounds, or 23.3% of their body weight. The trial did not test long-term safety or results after stopping the drug.

Original reporting
Published Nov 18, 2026, 10:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lilly's EloraTZP Brought Up to 77% of Adults With Diabetes to Normal Blood Sugar in Phase 2 Trial — source image
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The new data add responder endpoints tied to diabetes control (normal blood sugar) and obesity status (moving out of obesity criteria), but the article stresses Phase 2-only evidence, undefined “normal” thresholds, and notable side-effect-driven discontinuations.

02

Market read

Traders may update expectations for Lilly’s obesity and diabetes pipeline based on incremental Phase 2 efficacy endpoints, while discounting for Phase 3 uncertainty and tolerability risk.

03

What to watch

The article notes the trial did not assess durability after stopping or whether patients could reduce diabetes meds, which are key for long-term value and payer impact.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session sentiment read-through from ObesityWeek presentation on Nov. 15

Background

EloraTZP is an investigational combination pairing eloralintide (amylin receptor targeting) with tirzepatide (GLP-1/GIP), with Lilly presenting Phase 2 results at ObesityWeek 2026.

Company-level read

Ticker impact

$LLYBullishMedium confidence
Context

Eli Lilly presented new Phase 2 data for EloraTZP at ObesityWeek, reporting up to 77% reaching normal blood sugar after 48 weeks.

Expected impact

Likely modest positive bias for sentiment around the program, tempered by the article’s emphasis on Phase 2 limitations and meaningful discontinuation from side effects.

Evidence & confidence

The article discloses fresh, company-presented outcomes (normal blood sugar and moving out of obesity criteria) plus quantified tolerability (combination discontinuation up to 27%) and lack of Phase 3 confirmation.

Market effects

Reinforces investor focus on next-gen obesity and diabetes combinations (amylin plus incretin pathways) and the importance of tolerability versus efficacy in read-throughs.

Primarily US large-cap biotech sentiment via Lilly’s pipeline update; limited direct regional spillover.

ObesityWeek is international, but the actionable signal is company-specific clinical progress rather than a global policy or supply shock.

Counterpoint

High “up to” responder rates may not translate to broader populations, and the combination’s discontinuation risk could limit adoption even if Phase 3 confirms efficacy.

Key entities

  • Eli Lilly

    Presented new Phase 2 EloraTZP outcomes at ObesityWeek, including responder rates for normal blood sugar and obesity criteria, plus tolerability metrics.

  • EloraTZP

    Investigational combination of eloralintide plus tirzepatide, studied in a Phase 2b trial over 48 weeks.

  • ObesityWeek 2026

    Venue where Lilly presented the updated Phase 2 data on Nov. 15, 2026.

Related articles

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$LLYMedAI 8/10

Stipple Bio Signs Up to $5.9B Oncology Deal With Eli Lilly

Eli Lilly has partnered with private biotech firm Stipple Bio on an oncology research deal potentially worth up to $5.9B. Stipple's technology aims to identify cancer-specific molecules, aiding Lilly's development of targeted therapies. Stipple will receive milestone payments, royalties, and an equity investment, while Lilly gains exclusive rights to resulting products. Stipple is also developing its own oncology pipeline, including STP-100, set for Phase 1 trials in 2027.

$LLYMed

Eli Lilly Pledges Up to $5.9 Billion for Stipple Bio Cancer Drug Alliance

Eli Lilly (LLY) has agreed to a global licensing and research collaboration with Stipple Bio, a private biotech company, to develop precision cancer therapies. Stipple Bio could receive up to $5.9 billion, including an upfront payment, equity investment, and milestone payments. Lilly gains exclusive worldwide rights to develop and sell therapies from the partnership. Separately, Lilly agreed to acquire Calytrix Bio for up to $1.5 billion in cash.